Hydrogel-Delivered GM-CSF Overcomes Nonresponsiveness to Hepatitis B Vaccine through the Recruitment and Activation of Dendritic Cells

作者: Ho-Yuan Chou , Xi-Zhang Lin , Wen-Yu Pan , Ping-Yi Wu , Chia-Ming Chang

DOI: 10.4049/JIMMUNOL.1001875

关键词:

摘要: The standard hepatitis B surface Ag (HBsAg) vaccine fails to induce anti-hepatitis Abs in 5-10% of healthy subjects, a phenomenon known as HBsAg nonresponsiveness, which is closely related HLA class II alleles and impaired Th cell responses these subjects. We hypothesized that GM-CSF, potent adjuvant enhancing the Ag-presentation activity APCs, might help generate nonresponders, subsequently providing for cells produce Abs. used thermosensitive biodegradable copolymer (hydrogel) system codeliver GM-CSF achieve maximal local cytokine at injection site. In responder mouse strains, hydrogel-formulated plus (Gel/HBs+GM) elicited much greater Ab titers proliferative than commercial aluminum-formulated or free HBsAg. effect Gel/HBs+GM was dependent upon release GM-CSF. More importantly, high HBsAg-specific B10.M mice, strain does not respond current because its H-2 haplotype. Analysis draining lymph nodes vaccine-treated mice revealed an elevated number CD11c(+) dendritic showing enhanced expression MHC variety costimulatory molecules. These results demonstrate represent simple effective method next-generation virus vaccines inducing nonresponders.

参考文章(62)
S. Viviani, A. Jack, A.J. Hall, N. Maine, M. Mendy, R. Montesano, H.C. Whittle, Hepatitis B vaccination in infancy in The Gambia: protection against carriage at 9 years of age. Vaccine. ,vol. 17, pp. 2946- 2950 ,(1999) , 10.1016/S0264-410X(99)00178-4
J Agosti, M Schiff, D Garner, T G Evans, B Graves, J L Holley, M L Barritt, The safety and efficacy of GM-CSF as an adjuvant in hepatitis B vaccination of chronic hemodialysis patients who have failed primary vaccination Clinical Nephrology. ,vol. 54, pp. 138- 142 ,(2000)
S S Chiou, H Obata, T Nakanishi, K Yamauchi, Nature of immunological non-responsiveness to hepatitis B vaccine in healthy individuals. Immunology. ,vol. 64, pp. 545- 550 ,(1988)
J L Hughes, J E Jones, A Moriarty, A McLachlan, G Bitter, D R Milich, Importance of subtype in the immune response to the pre-S(2) region of the hepatitis B surface antigen. II. Synthetic Pre-S(2) immunogen. Journal of Immunology. ,vol. 144, pp. 3544- 3551 ,(1990)
N Stute, VM Santana, JH Rodman, MJ Schell, JN Ihle, WE Evans, Pharmacokinetics of subcutaneous recombinant human granulocyte colony-stimulating factor in children. Blood. ,vol. 79, pp. 2849- 2854 ,(1992) , 10.1182/BLOOD.V79.11.2849.2849
Keith E. Langley, Janice L. Hughes, Joyce E. Jones, Alan Mclachlan, George B. Thornton, David R. Milich, Importance of subtype in the immune response to the pre-S(2) region of the hepatitis B surface antigen. I. T cell fine specificity. Journal of Immunology. ,vol. 144, pp. 3535- 3543 ,(1990)
Wei Kuang Chi, Wen Chang Lin, Mi Hua Tao, Bor Luen Chiang, Yueh Lun Lee, Yen Teen Chen, Yen Hung Chow, Development of Th1 and Th2 Populations and the Nature of Immune Responses to Hepatitis B Virus DNA Vaccines Can Be Modulated by Codelivery of Various Cytokine Genes Journal of Immunology. ,vol. 160, pp. 1320- 1329 ,(1998)
Vincenzo Bronte, Elisa Apolloni, Anna Cabrelle, Roberto Ronca, Paolo Serafini, Paola Zamboni, Nicholas P. Restifo, Paola Zanovello, Identification of a CD11b(+)/Gr-1(+)/CD31(+) myeloid progenitor capable of activating or suppressing CD8(+) T cells. Blood. ,vol. 96, pp. 3838- 3846 ,(2000) , 10.1182/BLOOD.V96.12.3838
L Bressler, A Alpert, P J Morrissey, S Gillis, L S Park, Granulocyte-macrophage colony-stimulating factor augments the primary antibody response by enhancing the function of antigen-presenting cells. Journal of Immunology. ,vol. 139, pp. 1113- 1119 ,(1987)